NASDAQ:HRMY

Harmony Biosciences Holdings Stock Insider Trading

Healthcare > Biotechnology

Buy HRMY

*Your capital is at risk

$35.24

-0.620 (-1.73%)

At Close: Jul 31, 2026

Harmony Biosciences Holdings Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 26.17. In total, the insiders bought 1.86M and sold 13.43M HRMY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	26.17
● Buy	1.86M shares
● Sell	13.43M shares
77% Buy Activity Weak Positive Correlation
Buy Signal Medium Confidence Jul 16, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 26.17. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (77% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 25, 2026 Sell	Common Stock F-InKind	Budur Kumar Chief Medical Officer	Officer	1 372 Value: $50.5K
Jan 25, 2026 Buy	Common Stock M-Exempt	Budur Kumar Chief Medical Officer	Officer	2 662 Value: $93.8K
Jan 25, 2026 Buy	Restricted Stock Units M-Exempt	Budur Kumar Chief Medical Officer	Officer	2 662 Value: $93.8K
Jan 25, 2026 Buy	Restricted Stock Units M-Exempt	Kapadia Sandip Chief Financial Officer	C-Suite Officer	4 725 Value: $166.5K
Jan 25, 2026 Buy	Common Stock M-Exempt	Kapadia Sandip Chief Financial Officer	C-Suite Officer	4 725 Value: $166.5K
Jan 25, 2026 Sell	Common Stock F-InKind	Kapadia Sandip Chief Financial Officer	C-Suite Officer	2 553 Value: $94.0K
Jan 25, 2026 Buy	Restricted Stock Units M-Exempt	Serafin Andrew Chief Strategy Officer	Officer	2 600 Value: $91.6K
Jan 25, 2026 Sell	Common Stock F-InKind	Serafin Andrew Chief Strategy Officer	Officer	1 126 Value: $41.5K
Jan 25, 2026 Buy	Restricted Stock Units M-Exempt	Dayno Jeffrey M. President, CEO	CEO / President	13 000 Value: $458.1K
Jan 25, 2026 Buy	Common Stock M-Exempt	Dayno Jeffrey M. President, CEO	CEO / President	13 000 Value: $458.1K
Jan 25, 2026 Buy	Common Stock M-Exempt	Serafin Andrew Chief Strategy Officer	Officer	2 600 Value: $91.6K
Jan 25, 2026 Sell	Common Stock F-InKind	Dayno Jeffrey M. President, CEO	CEO / President	5 654 Value: $208.2K
Jan 24, 2026 Buy	Restricted Stock Units M-Exempt	Dayno Jeffrey M. President, CEO	CEO / President	10 500 Value: $370.0K
Jan 24, 2026 Sell	Common Stock F-InKind	Budur Kumar Chief Medical Officer	Officer	1 153 Value: $42.5K
Jan 24, 2026 Sell	Common Stock F-InKind	Serafin Andrew Chief Strategy Officer	Officer	1 116 Value: $41.1K
Jan 24, 2026 Buy	Common Stock M-Exempt	Serafin Andrew Chief Strategy Officer	Officer	2 500 Value: $88.1K
Jan 24, 2026 Buy	Restricted Stock Units M-Exempt	Serafin Andrew Chief Strategy Officer	Officer	2 500 Value: $88.1K
Jan 24, 2026 Sell	Common Stock F-InKind	Kapadia Sandip Chief Financial Officer	C-Suite Officer	2 239 Value: $82.4K
Jan 24, 2026 Buy	Common Stock M-Exempt	Kapadia Sandip Chief Financial Officer	C-Suite Officer	3 813 Value: $134.4K
Jan 24, 2026 Buy	Restricted Stock Units M-Exempt	Kapadia Sandip Chief Financial Officer	C-Suite Officer	3 813 Value: $134.4K
Jan 24, 2026 Buy	Restricted Stock Units M-Exempt	Budur Kumar Chief Medical Officer	Officer	2 188 Value: $77.1K
Jan 24, 2026 Buy	Common Stock M-Exempt	Budur Kumar Chief Medical Officer	Officer	2 188 Value: $77.1K
Jan 24, 2026 Buy	Common Stock M-Exempt	Dayno Jeffrey M. President, CEO	CEO / President	10 500 Value: $370.0K
Jan 24, 2026 Sell	Common Stock F-InKind	Dayno Jeffrey M. President, CEO	CEO / President	4 785 Value: $176.2K
Jan 22, 2026 Buy	Restricted Stock Units A-Award	Dayno Jeffrey M. President, CEO	CEO / President	52 900 Value: $1.94M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT HARMONY BIOSCIENCES HOLDINGS, INC.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmo...

Read Full Profile Here